Related Experiment Video
Updated: May 5, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
Agnieszka Owczarczyk-Saczonek1, Henryk Witmanowski, Waldemar Placek
1Department of Dermatology, Sexually Transmited Diseases and Clinical Immunology, Municipal Hospital, Olsztyn, Poland. Head: Prof. Waldemar Placek MD, PhD.
Abstract:
Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Acne Infection
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
